Efficacy and safety of Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting

Efficacy and safety of Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting - Efficacy and safety of Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053865

Enrollment

100

Registered

2024-03-14

Start date

2024-03-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients receiving highly or moderately emetogenic chemotherapy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Adult 2)Patients receiving highly or moderately emetogenic chemotherapy

Exclusion criteria

Exclusion criteria: patients with severe dementia

Design outcomes

Primary

Measure	Time frame
1)Common Terminology Criteria for Adverse Events (CTCAE) v5.0 2)MASCC Antinausea and vomiting Tool (MAT)	—

Countries

Japan

Contacts

Public ContactKosuke Nishizawa

Toho University Sakura Medical Center Department of Pharmacy

k-nishizawa@med.toho-u.ac.jp043-462-8811

Outcome results